Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

BACKGROUND: Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of β-hydroxy-β-methylbutyrate, arginine, and glutamine (HMB/Arg/Gln) was assessed in newly diagnosed patients. METHODS: NOURISH, a prospective, two-arm, open-label, multi-centre,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascoe, Jennifer, Jackson, Aimee, Gaskell, Charlotte, Gaunt, Claire, Thompson, Joyce, Billingham, Lucinda, Steven, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274132/
https://www.ncbi.nlm.nih.gov/pubmed/34247580
http://dx.doi.org/10.1186/s12885-021-08519-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274132/
https://www.ncbi.nlm.nih.gov/pubmed/34247580
http://dx.doi.org/10.1186/s12885-021-08519-8

Ejemplares similares